- Home
- ELVR vs SPRY Comparison
ELVR vs SPRY Comparison
Compare ELVR & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVR | SPRY |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | Australia | United States |
| Employees | 230 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.8M | 823.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELVR | SPRY |
|---|---|---|
| Price | $98.74 | $8.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 74.9K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $90.73 | $87.40 |
| Revenue Next Year | $42.59 | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.55 | $6.66 |
| 52 Week High | $99.98 | $18.63 |
Technical Indicators
Market Signals| Indicator | ELVR | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 71.83 | 53.70 |
| Support Level | $49.59 | $8.61 |
| Resistance Level | N/A | $9.46 |
| Average True Range (ATR) | 3.50 | 0.49 |
| MACD | 0.52 | 0.11 |
| Stochastic Oscillator | 93.35 | 53.39 |
Price Performance
Historical ComparisonAbout ELVR Sayona Mining Limited American Depository Shares
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.